EICHORCondition: Postoperative Pain · Sponsor: Heron Therapeutics
This is a Phase 3, randomized, double-blind, saline placebo- and active-controlled, multicenter study to evaluate the analgesic efficacy and safety of HTX 011 administered via local administration into the surgical site in subjects undergoing unilateral open inguinal herniorrhaphy.
This description comes directly from the study's public registry record.
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
| Eliza Coffee Memorial Hospital | Florence, Alabama, United States | — |
| Shoals Medical Trials, Inc. | Sheffield, Alabama, United States | — |
| Arizona Research Center | Phoenix, Arizona, United States | — |
| Anaheim Clinical Trials, LLC | Anaheim, California, United States | — |
| Trovare Clinical Research, Inc. | Bakersfield, California, United States | — |
| Alliance Research Centers | Laguna Hills, California, United States | — |
| Lotus Clinical Research, LLC | Pasadena, California, United States | — |
| HD Research Corp | Riverside, California, United States | — |
| American Institute of Research | Whittier, California, United States | — |
| Yale University School of Medicine | New Haven, Connecticut, United States | — |
| Cornerstone Research Institute, LLC | Longwood, Florida, United States | — |
| Park Place Surgery Center | Maitland, Florida, United States | — |
+ 12 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03237481